AQST News and Press, Aquestive Therapeutics Inc. From 05/08/19

WARREN, N.J. , May 8, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today reported financial results for...

SAINT LAURENT, Quebec, May 08, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc. (NASDAQ:AQST) (...

WARREN, N.J. , May 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced the appointment of Daniel Barber to the new po...

Aquestive Therapeutics ( AQST ) has been on my radar since its IPO back in July of 2018. Unfortunately, the company has had a few regulatory setbacks with some partnered and secondary product candidates that have cut the share price. These setbacks have prevented me from buying into the stoc...

WARREN, N.J. , April 17, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the first qua...

Acer Therapeutics ( ACER ) - The company announced publication of long-term data from a cohort of COL3A1-positive Vascular Ehlers-Danlos Syndrome (vEDS) patients in the Journal of the American College of Cardiology. The trial describes outcomes for 144 COL3A1-positive vEDS patients cli...

WARREN, N.J. , April 16, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Food and Drug Administration (F...

WARREN, N.J. , March 25, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that management will present at the H.C. Wainwright...

Aquestive Therapeutics, Inc. (AQST) Q4 2018 Earnings Conference Call March 14, 2019 08:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Dan Barber - Chief ...

Aquestive Therapeutics (NASDAQ: AQST ): Q4 GAAP EPS of -$0.56 in-line. More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...